McKirdy H C
Department of Surgery, University Hospital of Wales, Cardiff, U.K.
Pharmacol Ther. 1988;38(3):429-52. doi: 10.1016/0163-7258(88)90013-7.
The evidence for, and possible roles of, inhibitory and excitatory non-adrenergic, non-cholinergic (NANC) nerves supplying smooth muscle, and the effects of putative transmitter candidates are considered for each of three main regions of the upper gastrointestinal tract: (A) the smooth muscle portion of the oesophagus and the oesophagogastric junction, (B) the stomach (fundus, body and antrum) and gastroduodenal junction and (C) the biliary tract and choledochoduodenal junction. The major points from human tissues are as follows: 1. Inhibitory (NANCI) nerves appear to be present in the muscularis externa of oesophagus, stomach and duodenum, with greater density in the circular than in the longitudinal muscle. 2. NANCI nerves are present in high density at the oesophagogastric and choledochoduodenal junctions. They may also be present at the gastroduodenal junction. The gall-bladder may have a very sparse NANCI innervation. 3. Excitatory (NANCE) nerves appear to be present throughout the upper gastrointestinal tract. 4. Many candidates need at present to be considered for the role of NANCE transmitter(s) in the human upper gastrointestinal tract but substance P still seems a likely contender for this role. 5. Fewer candidates are at present generally available for the role of NANCI transmitter(s), with VIP and ATP being leading contenders. However, in the human upper gastrointestinal tract the evidence for ATP is not good, and VIP still remains the favourite candidate except in the gall-bladder, where its role remains to be elucidated.
本文考虑了支配平滑肌的抑制性和兴奋性非肾上腺素能、非胆碱能(NANC)神经的证据及其可能作用,以及假定的递质候选物的作用,这些是针对上消化道三个主要区域分别进行探讨的:(A)食管平滑肌部分及食管胃交界处;(B)胃(胃底、胃体和胃窦)及胃十二指肠交界处;(C)胆道及胆总管十二指肠交界处。来自人体组织的要点如下:1. 抑制性(NANCI)神经似乎存在于食管、胃和十二指肠的肌层,环形肌中的密度高于纵行肌。2. NANCI神经在食管胃交界处和胆总管十二指肠交界处高密度存在。它们也可能存在于胃十二指肠交界处。胆囊可能有非常稀疏的NANCI神经支配。3. 兴奋性(NANCE)神经似乎存在于整个上消化道。4. 目前许多候选物都被认为可能是人类上消化道中NANCE递质的角色,但P物质似乎仍是这一角色的有力竞争者。5. 目前可作为NANCI递质角色的候选物较少,血管活性肠肽(VIP)和三磷酸腺苷(ATP)是主要竞争者。然而,在人类上消化道中,支持ATP的证据不足,除了在胆囊中其作用仍有待阐明外,VIP仍是最有可能的候选物。